Avacta Group (LSE:AVCT) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AVCT Avacta Group PLC LSE:AVCT
28 GF Score
Price £0.69
GF Value £0.48
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LSE:AVCT
28GF Score
Avacta Group PLC LSE:AVCT
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avacta Group (LSE:AVCT) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of £0.69 is trading 43.8% above its estimated GF Value™ of £0.48. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for LSE:AVCT:

  • Interest Received:
  • GF Value™: £0.48 vs. price of £0.69 (43.8% above fair value)
  • GF Score™: 28/100 with 8 warning signs

No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score

Get the complete analysis for LSE:AVCT

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.69
Price
£0.48
GF Value